Brokerage firm Prabhudas Lilladher has set a target price of Rs 5,500 for Torrent Pharmaceuticals, highlighting strong second-quarter performance and merger synergies. The firm believes the company’s ability to resolve supply chain hurdles and integrate acquired businesses will drive future profitability.
Torrent Pharmaceuticals, a major player in the Indian drug market, has received an updated target price of Rs 5,500 from brokerage firm Prabhudas Lilladher. This adjustment follows the company's reporting of a 20% increase in core operating profit for the second quarter of the 2027 fiscal year. The firm's positive outlook is largely driven by the company’s success in fixing supply chain issues, specifically the improved availability of its semaglutide injectable products, which had previously created a bottleneck for the business.
The brokerage report emphasizes the benefits of integrating JB Chemicals & Pharma. Torrent has managed to capture cost savings faster than initially projected, which is helping to improve profit margins. By focusing on chronic therapies—treatments for long-term health conditions like diabetes and heart disease—the company has solidified its position as the fifth-largest pharmaceutical player in India. This focus on higher-value treatments is designed to provide more stable revenue compared to the market for acute, short-term medicines.
However, investors should be aware of the inherent risks in the pharmaceutical sector. Like its peers, Torrent faces the constant pressure of government price controls on essential medicines in the domestic market. Additionally, the company must manage complex regulatory landscapes, including potential audits from international health agencies like the USFDA. Any delay in these approvals or negative inspection reports can quickly disrupt export revenues. Furthermore, while the current integration of acquired businesses is performing well, the long-term success of such moves often depends on maintaining high operational efficiency and managing debt, which remains a key factor for any company undergoing heavy expansion.
Looking ahead, the market will be watching to see if the company can maintain its current pace of profit growth. A primary monitorable will be the company’s ability to translate its revenue synergies into actual cash flow by the 2028 fiscal year. Investors may also track management commentary on how they plan to further diversify their portfolio and whether they face any fresh pricing pressures in either the domestic or international markets.